Michael Martens PhD
Research Areas of Interest
Clinical TrialMachine LearningObservational StudySurvival AnalysisOncologyAdaptive Trial DesignBlood and Marrow Transplant ResearchBayesian StatisticsVariable SelectionPublications (50)
Group sequential clinical trial designs for composite endpoints incorporating recurrent and terminal events. (Lian Q, Ahn KW, Kim S, Logan BR, Solh M, Martens MJ) Biometrics 2026 Jul 01;82(3) PMID: 42496177 PMCID: PMC13397504 SCOPUS ID: 2-s2.0-105045424465 07/24/2026 Infections Within 100 Days of Idecabtagene Vicleucel and Impact on Survival for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis. (Wudhikarn K, Gowda L, Ye Q, Oloyede T, Martens M, Banerjee R, Devarakonda SS, Liu H, Herr MM, Young JH, Jain T, Dias A, Nishihori T, Mirza AS, Ganguly S, Beitinjaneh AM, Aljurf M, Wirk B, Farhadfar N, Efebera YA, Perales MA, Ebens CL, Murthy HS, Hill JA, Dandoy CE, Hong S, Boghdadly ZE, Akhtar OS, Auletta JJ, Huppler AR, Abid MB, CIBMTR) Transplant Cell Ther 2026 Jun 27 PMID: 42364732 PMCID: PMC13382910 SCOPUS ID: 2-s2.0-105044743555 06/28/2026 TITE-safety: a robust time-to-event safety monitoring approach for clinical trials. (Martens MJ, Lian Q, Logan BR) Biometrics 2026 Apr 09;82(2) PMID: 42201841 PMCID: PMC13215099 SCOPUS ID: 2-s2.0-105040601853 05/27/2026 Antigen-specific T-cell responses to SARS-CoV-2 vaccination after hematopoietic cell transplant or CAR T-cell therapy. (Einarsdottir S, Fei T, Singh K, Martens M, Young JH, Bhavsar K, Kou J, Chen M, Lee LW, Baluch A, Dhodapkar MV, Nakamura R, Peyton K, Shahid Z, Armistead P, Westervelt P, McCarty J, McGuirk J, Hamadani M, Sharon E, Spahn A, Toor AA, Waldvogel S, Greenberger LM, Auletta JJ, Horowitz MM, Riches ML, Hosszu K, Hill JA, DeWolf S, Perales MA) Blood Adv 2026 Jun 09;10(11):3945-3959 PMID: 41941698 PMCID: PMC13235446 SCOPUS ID: 2-s2.0-105040358681 04/06/2026 Differential effects of two common GVHD prophylaxis regimens on the gut microbiome: Results from the BMT CTN 1801 study. (Wirbel J, Saber W, Martens MJ, Peled JU, Andermann TM, Fei T, Brooks EF, Doyle B, Pincus NB, Jenq RR, Bar M, Bolaños-Meade J, Bratrude B, Chhabra S, Choi SW, Clark W, Das S, Elmariah H, Gooptu M, Holtan SG, Jones RJ, Levine JE, Logan BR, Al Malki MM, Murthy HS, Rashidi A, Rezvani AR, Riches ML, Runaas L, Sandhu K, Spahn A, Sung AD, van den Brink MRM, Horowitz MM, Hamadani M, Kean LS, Perales MA, Bhatt AS) bioRxiv 2026 Feb 19 PMID: 41756883 PMCID: PMC12934721 02/27/2026 The BIOPREVENT machine-learning algorithm predicts chronic graft-versus-host disease and mortality risk using posttransplant biomarkers. (Martens MJ, Dutta D, Yu Y, Rein LE, Ritz J, Logan BR, Paczesny S) J Clin Invest 2026 Feb 16;136(4) PMID: 41697751 PMCID: PMC12904722 SCOPUS ID: 2-s2.0-105030225247 02/16/2026 2 CitationsCovariate-Adjusted Group Sequential Comparisons of Survival Probabilities. (Zhang P, Logan B, Martens MJ) Stat Med 2025 Dec;44(28-30):e70339 PMID: 41350757 PMCID: PMC12822512 SCOPUS ID: 2-s2.0-105023969704 12/06/2025 The Cox Model With Adaptive Fused Group Bridge Penalty to Incorporate Historical Data Into the Analysis of Clinical Trials With an Application to BMT CTN 1101. (Fang X, Kim S, Martens MJ, Logan BR, Woo Ahn K) Stat Med 2025 Aug;44(18-19):e70233 PMID: 40817818 PMCID: PMC12614236 SCOPUS ID: 2-s2.0-105013464110 08/16/2025 Real-world outcomes of infections following tisagenlecleucel in patients with B-cell ALL: a CIBMTR analysis. (Rangarajan HG, Satwani P, Herr MM, Chen M, Martens MJ, Wudhikarn K, John S, Fabrizio VA, Hsieh EM, Kelkar AH, Doherty E, Marks DI, Ringden O, Friend B, Kelly MS, Farhadfar N, Prestidge T, Hossain NM, Liu H, Hashmi S, Modi D, Winestone LE, El Boghdadly Z, Murthy HS, Perales MA, Chemaly RF, Dandoy CE, Hill JA, Huppler A, Riches M, Auletta JJ) Blood Adv 2025 Nov 11;9(21):5489-5500 PMID: 40737539 PMCID: PMC12607035 SCOPUS ID: 2-s2.0-105022753658 07/30/2025 5 CitationsInfection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTR. (Wudhikarn K, Herr MM, Chen M, Martens MJ, Baird JH, Gowda L, Rangarajan HG, Abid MB, Kharfan-Dabaja MA, Williams KM, Ganguly S, Young JH, Sharma A, Fatobene G, Jain T, Kanakry CG, Modi D, Grover NS, Salem B, Batista MV, Vergidis P, Yin DE, Beitinjaneh AM, Kelkar AH, Nishihori T, Holter Chakrabarty J, Gergis U, Smith M, El Boghdadly Z, Dandoy CE, Murthy HS, Huppler AR, Perales MA, Chemaly RF, Hill JA, Riches M, Auletta JJ) Blood Adv 2025 Nov 11;9(21):5460-5472 PMID: 40435511 PMCID: PMC12607006 SCOPUS ID: 2-s2.0-105011883246 05/28/2025 15 CitationsSequential monitoring of time-to-event safety endpoints in clinical trials. (Martens MJ, Lian Q, Geller NL, Leifer ES, Logan BR) Clin Trials 2025 Jun;22(3):267-278 PMID: 40396502 PMCID: PMC12096354 SCOPUS ID: 2-s2.0-85213536554 05/21/2025 3 CitationsAccurate prediction of absolute prokaryotic abundance from DNA concentration. (Wirbel J, Andermann TM, Brooks EF, Evans L, Groth A, Dvorak M, Chakraborty M, Palushaj B, Reynolds GZM, Porter IE, Al Malki M, Rezvani A, Gooptu M, Elmariah H, Runaas L, Fei T, Martens MJ, Bolaños-Meade J, Hamadani M, Holtan S, Jenq R, Peled JU, Horowitz MM, Poston KL, Saber W, Kean LS, Perales MA, Bhatt AS) Cell Rep Methods 2025 May 19;5(5):101030 PMID: 40300608 PMCID: PMC12146642 SCOPUS ID: 2-s2.0-105003827989 04/30/2025 4 CitationsImpact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703. (Abedin S, Martens MJ, Bolaños-Meade J, Al Malki MM, Lian Q, Runaas L, Elmariah H, Gooptu M, Larkin KT, Shaffer BC, Loren AW, Solh M, Alousi AM, Jamy OH, Perales MA, Rezvani A, Bhatt A, El Jurdi N, Yao JM, Applegate K, Kean LS, Efebera YA, Reshef R, Clark W, Leifer E, Saber W, Horowitz MM, Jones RJ, Holtan SG, Hamadani M) Blood Adv 2025 Jul 22;9(14):3495-3501 PMID: 40305657 PMCID: PMC12274666 SCOPUS ID: 2-s2.0-105011266148 04/30/2025 7 CitationsDelayed T-cell recovery after hematopoietic cell transplantation is associated with decreased overall survival in adults. (Perales MA, Riches M, He N, Martens MJ, Chemaly RF, Dandoy CE, Hill JA, Diaz MA, Hashmi S, Prockop S, Lazarus HM, Beitinjaneh AM, Hildebrandt GC, Auletta JJ, Szabolcs P) Blood Adv 2025 Jul 22;9(14):3502-3517 PMID: 40249911 PMCID: PMC12274672 SCOPUS ID: 2-s2.0-105011262643 04/18/2025 3 CitationsGraft-versus-host disease prophylaxis shapes T cell biology and immune reconstitution after hematopoietic cell transplant. (Siegel SJ, DeWolf S, Schmalz J, Saber W, Dong J, Martens MJ, Logan B, Albanese A, Iovino L, Chen E, Kaminski J, Neuberg D, Hebert K, Keskula P, Zavistaski J, Steinberg L, Schichter I, Cagnin L, Hernandez V, Warren M, Applegate K, Bar M, Chhabra S, Choi SW, Clark W, Das S, Jenq R, Jones RJ, Levine JE, Murthy H, Rashidi A, Riches M, Sandhu K, Sung AD, Larkin K, Al Malki MM, Gooptu M, Elmariah H, Alousi A, Runaas L, Shaffer B, Rezvani A, El Jurdi N, Loren AW, Scheffey D, Sanders C, Hamadani M, Dudakov J, Bien S, Robins H, Horowitz M, Bolaños-Meade J, Holtan S, Bhatt AS, Perales MA, Kean LS) medRxiv 2025 Feb 26 PMID: 40061351 PMCID: PMC11888538 03/10/2025 Correction: Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002. (Meyers G, Hamadani M, Martens M, Ali H, Chevallier P, Choe H, Harris AC, Holler E, van Hooren E, Klaassen W, Leifer E, van Oosterhout Y, Perez L, Pusic I, Stelljes M, van der Velden W, Ammatuna E, Beauvais D, Cornillon J, Maziarz RT, Schetelig J, Romeril J, MacMillan ML, Levine JE, Socié G) Bone Marrow Transplant 2025 May;60(5):746 PMID: 40016514 SCOPUS ID: 2-s2.0-85219054353 02/28/2025 Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703. (Holtan SG, Bolaños-Meade J, Al Malki MM, Wu J, Kitko CL, Reshef R, Rezvani AR, Shaffer BC, Solh MM, Yao JM, Runaas L, Elmariah H, Larkin KT, El Jurdi N, Gooptu M, Loren AW, Hall AC, Alousi AM, Jamy O, Clark W, Kean L, Bhatt AS, Perales MA, Applegate K, Efebera YA, Leifer E, Jones RJ, Horowitz MM, Mattila D, Saber W, Hamadani M, Martens MJ) J Clin Oncol 2025 Mar 10;43(8):912-918 PMID: 39752608 PMCID: PMC12124660 SCOPUS ID: 2-s2.0-85214844948 01/03/2025 9 CitationsTest Statistics and Statistical Inference for Data With Informative Cluster Sizes. (Kim S, Martens MJ, Ahn KW) Biom J 2025 Feb;67(1):e70021 PMID: 39686682 PMCID: PMC12658914 SCOPUS ID: 2-s2.0-85212263178 12/17/2024 SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study. (Hill JA, Martens MJ, Young JH, Bhavsar K, Kou J, Chen M, Lee LW, Baluch A, Dhodapkar MV, Nakamura R, Peyton K, Howard DS, Ibrahim U, Shahid Z, Armistead P, Westervelt P, McCarty J, McGuirk J, Hamadani M, DeWolf S, Hosszu K, Sharon E, Spahn A, Toor AA, Waldvogel S, Greenberger LM, Auletta JJ, Horowitz MM, Riches ML, Perales MA) Clin Infect Dis 2024 Aug 16;79(2):542-554 PMID: 38801746 PMCID: PMC11327798 SCOPUS ID: 2-s2.0-85201391712 05/27/2024 28 CitationsCorrigendum to "Designing and conducting a clinical trial in blood and marrow transplantation" [Best Pract Res Clin Haematol 36 (2023) 101471]. (Martens MJ, Gao Y, Szabo A) Best Pract Res Clin Haematol 2024 Mar;37(1):101538 PMID: 38490769 PMCID: PMC11748327 SCOPUS ID: 2-s2.0-85184062968 03/16/2024 Cystic Brain Metastasis Outcomes After Gamma Knife Radiation Therapy. (Amidon RF, Livingston K, Kleefisch CJ, Martens M, Straza M, Puckett L, Schultz CJ, Mueller WM, Connelly JM, Noid G, Morris K, Bovi JA) Adv Radiat Oncol 2024 Jan;9(1):101304 PMID: 38260234 PMCID: PMC10801666 SCOPUS ID: 2-s2.0-85167453267 01/23/2024 3 CitationsStatistical rules for safety monitoring in clinical trials. (Martens MJ, Logan BR) Clin Trials 2024 Apr;21(2):152-161 PMID: 37877375 PMCID: PMC11003847 SCOPUS ID: 2-s2.0-85174803819 10/25/2023 8 CitationsIncidence and Impact of Fungal Infections in Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis and Haploidentical Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis. (Papanicolaou GA, Chen M, He N, Martens MJ, Kim S, Batista MV, Bhatt NS, Hematti P, Hill JA, Liu H, Nathan S, Seftel MD, Sharma A, Waller EK, Wingard JR, Young JH, Dandoy CE, Perales MA, Chemaly RF, Riches M, Ustun C) Transplant Cell Ther 2024 Jan;30(1):114.e1-114.e16 PMID: 37775070 PMCID: PMC10872466 SCOPUS ID: 2-s2.0-85176212764 09/30/2023 23 CitationsAnti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002. (Meyers G, Hamadani M, Martens M, Ali H, Chevallier P, Choe H, Harris AC, Holler E, van Hooren E, Klaassen W, Leifer E, van Oosterhout Y, Perez L, Pusic I, Stelljes M, van der Velden W, Ammatuna E, Beauvais D, Cornillon J, Maziarz RT, Schetelig J, Romeril J, MacMillan ML, Levine JE, Socié G) Bone Marrow Transplant 2023 Dec;58(12):1416-1418 PMID: 37749187 PMCID: PMC11732251 SCOPUS ID: 2-s2.0-85172133108 09/26/2023 3 CitationsAllogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study. (Versluis J, Saber W, Tsai HK, Gibson CJ, Dillon LW, Mishra A, McGuirk J, Maziarz RT, Westervelt P, Hegde P, Mukherjee D, Martens MJ, Logan B, Horowitz M, Hourigan CS, Nakamura R, Cutler C, Lindsley RC, Blood and Marrow Transplant Clinical Trials Network) J Clin Oncol 2023 Oct 01;41(28):4497-4510 PMID: 37607457 PMCID: PMC10552956 SCOPUS ID: 2-s2.0-85175320632 08/23/2023 82 CitationsSample size and power determination for multiparameter evaluation in nonlinear regression models with potential stratification. (Martens MJ, Kim S, Ahn KW) Biometrics 2023 Dec;79(4):3916-3928 PMID: 37357412 PMCID: PMC10749377 SCOPUS ID: 2-s2.0-85162954172 06/26/2023 Designing and conducting a clinical trial in blood and marrow transplantation. (Martens MJ, Gao Y, Szabo A) Best Pract Res Clin Haematol 2023 Jun;36(2):101471 PMID: 37353295 PMCID: PMC10845212 SCOPUS ID: 2-s2.0-85159403396 06/24/2023 1 CitationPost-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. (Bolaños-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, Elmariah H, Rezvani AR, Gooptu M, Larkin KT, Shaffer BC, El Jurdi N, Loren AW, Solh M, Hall AC, Alousi AM, Jamy OH, Perales MA, Yao JM, Applegate K, Bhatt AS, Kean LS, Efebera YA, Reshef R, Clark W, DiFronzo NL, Leifer E, Horowitz MM, Jones RJ, Holtan SG, BMT CTN 1703 Investigators) N Engl J Med 2023 Jun 22;388(25):2338-2348 PMID: 37342922 PMCID: PMC10575613 SCOPUS ID: 2-s2.0-85164529275 06/21/2023 22 CitationsHigh-Grade Pneumonitis Events in Patients With Unresectable, Locally Advanced NSCLC Treated With Definitive Chemoradiation Followed by Adjuvant Durvalumab. (Ellison C, Martens M, Alvarez Argote J, Benz S, Currey A, Johnstone C, Klawikowski S, Livingston K, Longo JM, Menon S, Ortiz de Choudens S, Puckett L, Retseck J, Shukla M, Thompson J, Gore E) JTO Clin Res Rep 2024 Dec;5(12):100537 PMID: 39555223 PMCID: PMC11567112 SCOPUS ID: 2-s2.0-85207777055 06/15/2023 3 CitationsSARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study. (Hill JA, Martens MJ, Young JH, Bhavsar K, Kou J, Chen M, Lee LW, Baluch A, Dhodapkar MV, Nakamura R, Peyton K, Shahid Z, Armistead P, Westervelt P, McCarty J, McGuirk J, Hamadani M, DeWolf S, Hosszu K, Sharon E, Spahn A, Toor AA, Waldvogel S, Greenberger LM, Auletta JJ, Horowitz MM, Riches ML, Perales MA) EClinicalMedicine 2023 May;59:101983 PMID: 37128256 PMCID: PMC10133891 SCOPUS ID: 2-s2.0-85153604229 05/02/2023 23 CitationsHealth-Related Quality of Life in Double Umbilical Cord Blood versus Haploidentical Marrow Transplantation: A Quality of Life Analysis Report of BMT CTN 1101. (El Jurdi N, Martens MJ, Brunstein CG, O'Donnell P, Lee SJ, D'Souza A, Logan B, Hong S, Singh AK, Sandhu K, Shapiro RM, Horowitz MM, Hamilton BK) Transplant Cell Ther 2023 Jul;29(7):467.e1-467.e5 PMID: 37088401 PMCID: PMC10330136 SCOPUS ID: 2-s2.0-85162230932 04/24/2023 6 CitationsHealth-related quality of life in reduced-intensity hematopoietic cell transplantation based on donor availability in patients aged 50-75 with advanced myelodysplastic syndrome: BMT CTN 1102. (Cusatis R, Martens MJ, Nakamura R, Cutler CS, Saber W, Lee SJ, Logan BR, Shaw BE, Gregory A, D'Souza A, Hamilton BK, Horowitz MM, Flynn KE) Am J Hematol 2023 Feb;98(2):229-250 PMID: 36251401 PMCID: PMC9839494 SCOPUS ID: 2-s2.0-85142150726 10/18/2022 18 CitationsA Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial. (Bashir Q, Nishihori T, Pasquini MC, Martens MJ, Wu J, Alsina M, Anasetti C, Brunstein C, Dawson P, Efebera Y, Gasparetto C, Geller N, Giralt S, Hall AC, Koreth J, McCarthy P, Scott E, Stadtmauer EA, Vesole DH, Hari P) Transplant Cell Ther 2023 Jun;29(6):358.e1-358.e7 PMID: 35840087 PMCID: PMC10442072 SCOPUS ID: 2-s2.0-85151326035 07/16/2022 7 CitationsClinical Characteristics and Outcomes of COVID-19 in Pediatric and Early Adolescent and Young Adult Hematopoietic Stem Cell Transplant Recipients: A Cohort Study. (Bhatt NS, Sharma A, St Martin A, Abid MB, Brown VI, Diaz Perez MA, Frangoul H, Gadalla SM, Herr MM, Krem MM, Lazarus HM, Martens MJ, Mehta PA, Nishihori T, Prestidge T, Pulsipher MA, Rangarajan HG, Williams KM, Winestone LE, Yin DE, Riches ML, Dandoy CE, Auletta JJ) Transplant Cell Ther 2022 Oct;28(10):696.e1-696.e7 PMID: 35798233 PMCID: PMC9251957 SCOPUS ID: 2-s2.0-85136313619 07/08/2022 12 CitationsLong term clinical outcomes and associated predictors of progression free survival in anal canal cancer (Beltrán Ponce SE, Erickson BA, Hall WA, Bedi M, Martens MJ, Siker M, Thomas J, George B, Ludwig K, Peterson C, Ridolfi T, Longo JM) Journal of Gastrointestinal Oncology February 2022;13(1):185-196 SCOPUS ID: 2-s2.0-85125562951 02/01/2022 2 CitationsLessons learned from early closure of a clinical trial for steroid-refractory acute GVHD. (Meyers G, Hamadani M, Martens M, Ali H, Choe H, Dawson P, Harris AC, van Hooren E, Klaassen W, Leifer E, MacMillan ML, van Oosterhout Y, Perez L, Pusic I, Vo P, Levine JE) Bone Marrow Transplant 2022 Feb;57(2):302-303 PMID: 34815518 PMCID: PMC8825705 SCOPUS ID: 2-s2.0-85119658579 11/25/2021 3 CitationsBiologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome. (Nakamura R, Saber W, Martens MJ, Ramirez A, Scott B, Oran B, Leifer E, Tamari R, Mishra A, Maziarz RT, McGuirk J, Westervelt P, Vasu S, Patnaik M, Kamble R, Forman SJ, Sekeres MA, Appelbaum F, Mendizabal A, Logan B, Horowitz M, Cutler C) J Clin Oncol 2021 Oct 20;39(30):3328-3339 PMID: 34106753 PMCID: PMC8791814 SCOPUS ID: 2-s2.0-85112086284 06/10/2021 137 CitationsAcute GVHD Diagnosis and Adjudication in a Multicenter Trial: A Report From the BMT CTN 1202 Biorepository Study. (Reshef R, Saber W, Bolaños-Meade J, Chen G, Chen YB, Ho VT, Ponce DM, Nakamura R, Martens MJ, Hansen JA, Levine JE) J Clin Oncol 2021 Jun 10;39(17):1878-1887 PMID: 33507810 PMCID: PMC8260916 SCOPUS ID: 2-s2.0-85108020505 01/29/2021 26 CitationsA unified approach to sample size and power determination for testing parameters in generalized linear and time-to-event regression models. (Martens MJ, Logan BR) Stat Med 2021 Feb 28;40(5):1121-1132 PMID: 33210321 PMCID: PMC8020892 SCOPUS ID: 2-s2.0-85096664064 11/20/2020 10 CitationsRandomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial. (Pidala J, Hamadani M, Dawson P, Martens M, Alousi AM, Jagasia M, Efebera YA, Chhabra S, Pusic I, Holtan SG, Ferrara JLM, Levine JE, Mielcarek M, Anasetti C, Antin JH, Bolaños-Meade J, Howard A, Logan BR, Leifer ES, Pritchard TS, Horowitz MM, MacMillan ML) Blood 2020 Jan 09;135(2):97-107 PMID: 31738834 PMCID: PMC6952830 SCOPUS ID: 2-s2.0-85077761109 11/19/2019 81 CitationsGroup sequential tests for treatment effect on survival and cumulative incidence at a fixed time point. (Martens MJ, Logan BR) Lifetime Data Anal 2020 Jul;26(3):603-623 PMID: 31729633 PMCID: PMC7365590 SCOPUS ID: 2-s2.0-85075483839 11/16/2019 2 CitationsFactors Associated With Successful Discontinuation of Immune Suppression After Allogeneic Hematopoietic Cell Transplantation. (Pidala J, Martens M, Anasetti C, Carreras J, Horowitz M, Lee SJ, Antin J, Cutler C, Logan B) JAMA Oncol 2020 Jan 01;6(1):e192974 PMID: 31556923 PMCID: PMC6763979 SCOPUS ID: 2-s2.0-85072756041 09/27/2019 28 CitationsLow Information Omnibus (LIO) priors for dirichlet process mixture models (Shi Y, Martens M, Banerjee A, Laud P) Bayesian Analysis 2019;14(3):677-702 SCOPUS ID: 2-s2.0-85069995277 01/01/2019 8 CitationsA group sequential test for treatment effect based on the Fine-Gray model. (Martens MJ, Logan BR) Biometrics 2018 Sep;74(3):1006-1013 PMID: 29534294 PMCID: PMC6146968 SCOPUS ID: 2-s2.0-85043497709 03/14/2018 6 CitationsIncreasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. (Muffly L, Pasquini MC, Martens M, Brazauskas R, Zhu X, Adekola K, Aljurf M, Ballen KK, Bajel A, Baron F, Battiwalla M, Beitinjaneh A, Cahn JY, Carabasi M, Chen YB, Chhabra S, Ciurea S, Copelan E, D'Souza A, Edwards J, Foran J, Freytes CO, Fung HC, Gale RP, Giralt S, Hashmi SK, Hildebrandt GC, Ho V, Jakubowski A, Lazarus H, Luskin MR, Martino R, Maziarz R, McCarthy P, Nishihori T, Olin R, Olsson RF, Pawarode A, Peres E, Rezvani AR, Rizzieri D, Savani BN, Schouten HC, Sabloff M, Seftel M, Seo S, Sorror ML, Szer J, Wirk BM, Wood WA, Artz A) Blood 2017 Aug 31;130(9):1156-1164 PMID: 28674027 PMCID: PMC5580273 SCOPUS ID: 2-s2.0-85028876059 07/05/2017 273 CitationsComparing outcomes of matched related donor and matched unrelated donor hematopoietic cell transplants in adults with B-Cell acute lymphoblastic leukemia. (Segal E, Martens M, Wang HL, Brazauskas R, Weisdorf D, Sandmaier BM, Khoury HJ, de Lima M, Saber W) Cancer 2017 Sep 01;123(17):3346-3355 PMID: 28452054 PMCID: PMC5568918 SCOPUS ID: 2-s2.0-85018961928 04/30/2017 25 CitationsAllogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma. (Cornell RF, Bachanova V, D'Souza A, Woo-Ahn K, Martens M, Huang J, Al-Homsi AS, Chhabra S, Copelan E, Diaz MA, Freytes CO, Gale RP, Ganguly S, Hamadani M, Hildebrandt G, Kamble RT, Kharfan-Dabaja M, Kindwall-Keller T, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Saad A, Usmani S, Vesole DH, Yared J, Mark T, Nieto Y, Hari P) Biol Blood Marrow Transplant 2017 Jan;23(1):60-66 PMID: 27789362 PMCID: PMC5182098 SCOPUS ID: 2-s2.0-85006371447 10/30/2016 17 CitationsPretransplantation Exercise and Hematopoietic Cell Transplantation Survival: A Secondary Analysis of Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0902). (Wingard JR, Wood WA, Martens M, Le-Rademacher J, Logan B, Knight JM, Jacobsen PB, Jim H, Majhail NS, Syrjala K, Rizzo JD, Lee SJ) Biol Blood Marrow Transplant 2017 Jan;23(1):161-164 PMID: 27742574 PMCID: PMC5182134 SCOPUS ID: 2-s2.0-85006489235 10/16/2016 14 CitationsPatient-Reported Outcomes and Socioeconomic Status as Predictors of Clinical Outcomes after Hematopoietic Stem Cell Transplantation: A Study from the Blood and Marrow Transplant Clinical Trials Network 0902 Trial. (Knight JM, Syrjala KL, Majhail NS, Martens M, Le-Rademacher J, Logan BR, Lee SJ, Jacobsen PB, Wood WA, Jim HSL, Wingard JR, Horowitz MM, Abidi MH, Fei M, Rawls L, Rizzo JD) Biol Blood Marrow Transplant 2016 Dec;22(12):2256-2263 PMID: 27565521 PMCID: PMC5116244 SCOPUS ID: 2-s2.0-84992110582 08/28/2016 32 CitationsAllogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival. (Dhakal B, D'Souza A, Martens M, Kapke J, Harrington AM, Pasquini M, Saber W, Drobyski WR, Zhang MJ, Hamadani M, Hari PN) Clin Lymphoma Myeloma Leuk 2016 Jul;16(7):379-86 PMID: 27160644 SCOPUS ID: 2-s2.0-84965053091 05/11/2016 22 Citations
© 2026 Clinical & Translational Science Institute